ALZpath inks Abbott licensing to push blood tests for Alzheimer’s disease
A global licensing deal could accelerate blood-based diagnostics for Alzheimer’s as companies compete on simpler testing.
By Mohammed Al-Shehri·· 3 min
1 briefing · “diagnostics”
A global licensing deal could accelerate blood-based diagnostics for Alzheimer’s as companies compete on simpler testing.